 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors considering a purchase of Kymera Therapeutics Inc (KYMR) shares, but cautious about paying the going market price of 14.46/share, might benefit from considering selling puts among the...

#36;12.50, Earn 11.5% Annualized Using Options

Kymera Therapeutics, Inc. (NASDAQ:KYMR  Get Free Report)s share price traded down 3.8% on Monday . The company traded as low as $16.84 and last traded at $16.84. 17,120 shares were...

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 3.8%

Osiris Therapeutics (OTCMKTS:OSIR  Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR  Get Free Report) are both small-cap medical companies, but which is the superior stock? We will...

Osiris Therapeutics (OTCMKTS:OSIR) versus Kymera Therapeutics (NASDAQ:KYMR) Financial Survey

KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023 Fast Track designation can...

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR  Get Free Report) have been given an average recommendation of Moderate Buy by the nine research firms that are presently...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts

Kymera Therapeutics (NASDAQ:KYMR  Get Free Report) and Palisade Bio (NASDAQ:PALI  Get Free Report) are both small-cap medical companies, but which is the superior investment? We will...

Analyzing Kymera Therapeutics (NASDAQ:KYMR) & Palisade Bio (NASDAQ:PALI)

California State Teachers Retirement System lifted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR  Free Report) by 2.3% during the first quarter, Holdings Channel.com reports...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by California State Teachers Retirement System

WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Free Report) have earned an average recommendation of Moderate Buy from the nine brokerages that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR  Get Free Report) has been assigned an average rating of Moderate Buy from the nine research firms that are currently covering the firm...

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $48.50

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Watchers	447
52-Wk Low	$14.20
52-Wk High	$39.85

Market Cap	$792.4M
Volume (M)	3,750.00
52-Wk High	$39.85
52-Wk Low	$14.20

KYMR Kymera Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals